Rituximab therapy for refractory scleritis: Results of a phase I/II dose-ranging, randomized, clinical trial

Eric B. Suhler, Lyndell L. Lim, Robert M. Beardsley, Tracy R. Giles, Sirichai Pasadhika, Shelly T. Lee, Alexandre De Saint Sardos, Nicholas J. Butler, Justine R. Smith, James T. Rosenbaum

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Objective: To determine whether rituximab, a monoclonal antibody against the B-lymphocyte antigen CD20, is effective in the treatment of refractory noninfectious scleritis.

Design: Prospective, dose-ranging, randomized, double-masked phase I/II clinical trial.

Participants: Twelve patients with noninfectious scleritis refractory to systemic corticosteroid and ≥1 other systemic immunosuppressive agent were enrolled from January 2007 to March 2010. Intervention: Subjects were randomly assigned to 500 (n = 5) or 1000 mg (n = 7) dosing arms of rituximab intravenous infusions (500 or 1000 mg), given at study days 1 and 15. Initial responders with breakthrough inflammation after study week 24 were offered treatment with an additional cycle of 2 open-label rituximab 1000 mg infusions.

Main Outcome Measures: Primary outcomes were reduction of inflammation, as measured with a validated scleritis disease grading scale (SGS) and reduction in corticosteroid dose by ≥50%. Patients were characterized as responders to study therapy if ≥1 of these endpoints showed improvement and neither showed evidence of worsening. Secondary outcomes were improvement in visual acuity, reduction in pain, and improvement in patient and physician-reported global health assessment.

Results: Of 12 enrolled patients, 9 met the SGS endpoint at or before week 24, and 4 additionally were able to reduce corticosteroid dose by ≥50%. With regard to secondary outcome measures, 11 and 9 patients showed improvement in patient and physician global health scores, respectively, and 7 patients had reduction in pain. Of 9 initial responders, 7 experienced breakthrough inflammation after 24 weeks and were treated with a second cycle of rituximab infusions. Four patients had significant objective or subjective worsening within 8 weeks of receiving rituximab; this event was averted in subsequent patients by treatment with peri-infusional oral corticosteroid. No other significant adverse events were noted. No differences in efficacy, toxicity, or likelihood of retreatment were noted between the dosing arms.

Conclusions: Rituximab was effective treatment for 9 of 12 enrolled patients with refractory, noninfectious scleritis at 24 weeks, although 7 required reinfusion with rituximab to maintain inflammatory control. The treatment was well-tolerated, and peri-infusional inflammatory exacerbations were managed successfully with oral corticosteroids. Further long-term studies are warranted to determine the safety and efficacy of rituximab in treating noninfectious scleritis and other ocular inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)1885-1891
Number of pages7
JournalOphthalmology
Volume121
Issue number10
DOIs
StatePublished - Oct 1 2014

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Rituximab therapy for refractory scleritis: Results of a phase I/II dose-ranging, randomized, clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Suhler, E. B., Lim, L. L., Beardsley, R. M., Giles, T. R., Pasadhika, S., Lee, S. T., De Saint Sardos, A., Butler, N. J., Smith, J. R., & Rosenbaum, J. T. (2014). Rituximab therapy for refractory scleritis: Results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology, 121(10), 1885-1891. https://doi.org/10.1016/j.ophtha.2014.04.044